Search Results - brett+prigaro

1 Results Sort By:
Novel anti-metastatic agents that reverse epithelial-mesenchymal transition (EMT) in cancer (CHD1L).
Colorectal cancer (CRC) is one of the most prevalent forms of cancer with over 150,000 new cases reported each year. Stage 4 CRC patients have very poor survival rates at only 11% and there are currently no effective therapeutics for treating metastatic CRC. The epithelial-mesenchymal transition (EMT) is a driving force for tumor progression, tumor...
Published: 12/1/2023   |   Inventor(s): Daniel LaBarbera, Qiong Zhou, Joshua Abbott, Hector Esquer, Brett Prigaro
Disease Areas Oncology
Category(s): Therapeutics
For inquiries, email: cuinnovations@cuanschutz.edu.     © 2024. All Rights Reserved. Powered by Inteum